<DOC>
	<DOCNO>NCT02459418</DOCNO>
	<brief_summary>Comparative PK study single SC application Afolia reference product ( US Gonal-f® ) . Objective : To demonstrate equivalence within 80 % -125 % margin reference product area curve ( AUC ) Afolia .</brief_summary>
	<brief_title>Comparative Pharmacokinetics AFOLIA US Gonal-f® RFF Redi-ject After Single Subcutaneous Application</brief_title>
	<detailed_description>To demonstrate equivalence within 80 % 125 % margin reference product baseline correct area follicle-stimulating hormone ( FSH ) serum concentration-time curve time zero last quantifiable concentration AFOLIA compare reference product ( United States [ US ] Gonal-f® RFF )</detailed_description>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>1 . Healthy female volunteer age 18 42 year ( inclusive ) Body mass index 18.0 32.0 kg/m2 ( inclusive ) 2 . Subjects use oral contraceptive least 3 month study entry prepare stop take oral contraception screen use effective nonhormonal method birth control completion 1 menstrual cycle last dose administration 3 . Women child bear potential must agree use effective nonhormonal contraception birth control completion 1 menstrual cycle last dose administration 4 . Subjects regular menstruation cycle ( 25 34 day ) initiation oral contraception 5 . Subjects ovaries 6 . Subjects negative drug abuse alcohol test screen admission 7 . Subjects healthy determine pre study medical history , physical examination 12Lead electrocardiogram ( ECG ) 8 . Subjects whose clinical laboratory test result clinically relevant acceptable investigator 9 . Subjects able willing give write informed consent 1 . Subjects conform inclusion criterion 2 . Subjects polycystic ovary syndrome 3 . Subjects develop follicle solid ovarian cyst &gt; 2 cm complex cyst regardless size 4 . Subjects history hypersensitivity FSH ( Ovary Hyperstimulation Syndrome ) 5 . Subjects impaired thyroid function ( treat untreated ) 6 . Subjects history malignant disease 7 . Subjects aspartate aminotransferase and/or alanine aminotransferase &gt; 2 x upper limit normal reference range 8 . Subjects clinically relevant finding ( ECG , blood pressure , physical , laboratory examination ) 9 . Subjects smoke history 5 cigarette per day 10 . Subjects evidence abuse drug alcoholic beverage 11 . Subjects positive screen hepatitis B surface antigen , antibody hepatitis C virus antibody human immunodeficiency virus 1/2 12 . Subjects participate clinical trial within 3 month prior study 13 . Subjects unlikely cooperate requirement study 14 . Subjects symptoms clinically relevant illness 3 week prior study day 1 15 . Subjects pregnant , lactate attempt become pregnant 16 . Subjects medical condition ( include know predisposition porphyria ) , opinion investigator , could interfere safety subject interfere objective study 17 . Subjects vegans medical dietary restriction 18 . Subjects communicate reliably investigator</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>42 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Afolia</keyword>
	<keyword>Follitropin</keyword>
</DOC>